{"id":"moxifloxacin-metronidazole-or-piperacillin-tazobactam","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Metallic taste (metronidazole)"},{"rate":null,"effect":"Tendinopathy (fluoroquinolone)"},{"rate":null,"effect":"Photosensitivity (fluoroquinolone)"}]},"_chembl":{"chemblId":"CHEMBL1200735","moleculeType":"Small molecule","molecularWeight":"437.90"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Moxifloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, while metronidazole is a nitroimidazole that generates reactive intermediates to damage anaerobic bacterial DNA. Alternatively, piperacillin/tazobactam combines a broad-spectrum penicillin with a beta-lactamase inhibitor to overcome resistance mechanisms. Together, these combinations provide synergistic coverage of gram-positive, gram-negative, and anaerobic pathogens.","oneSentence":"This is a combination antibiotic regimen that uses fluoroquinolone and nitroimidazole agents (or beta-lactam with beta-lactamase inhibitor) to provide broad-spectrum coverage against aerobic and anaerobic bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:14.398Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intra-abdominal infections with mixed aerobic and anaerobic flora"},{"name":"Complicated appendicitis or peritonitis"}]},"trialDetails":[{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT00629135","phase":"PHASE3","title":"Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2005-11-15","conditions":"Abscess, Intra-Abdominal","enrollment":180},{"nctId":"NCT02168816","phase":"PHASE2","title":"Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis","status":"TERMINATED","sponsor":"Loyola University","startDate":"2014-03-19","conditions":"Osteomyelitis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6931,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Moxifloxacin/Metronidazole or Piperacillin/Tazobactam","genericName":"Moxifloxacin/Metronidazole or Piperacillin/Tazobactam","companyName":"Hannover Medical School","companyId":"hannover-medical-school","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination antibiotic regimen that uses fluoroquinolone and nitroimidazole agents (or beta-lactam with beta-lactamase inhibitor) to provide broad-spectrum coverage against aerobic and anaerobic bacteria. Used for Intra-abdominal infections with mixed aerobic and anaerobic flora, Complicated appendicitis or peritonitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}